bioAffinity Seeks Shareholder Approval for Warrant Exercises, Future Offerings, and Authorized Share Reduction
BIAF is trading near its 52-week low of $3.76 (3.7% above the low) on light trading volume (0.1× avg).
Summary
bioAffinity Technologies filed a preliminary proxy seeking shareholder approval for warrant exercises from two recent private placements, authorization for up to 10 million shares in future offerings at up to 35% discount, and a reduction in authorized shares from 350 million to 200 million.
Key Events · Corporate Governance and Compliance · BIAF
-
Warrant Exercise Approvals Sought
Shareholders are asked to approve issuance of up to 1,128,272 shares upon exercise of August 2026 warrants at $4.9757 per share and 980,072 shares upon exercise of October 2026 warrants at $6.122 per share, potentially raising up to $11.6 million in gross proceeds.
-
Future Offering Authorization
Proposal 3 seeks authority to issue up to 10,000,000 shares in non-public offerings at discounts of up to 35% below market price, with aggregate consideration capped at $10 million — representing potential dilution of approximately 857% relative to the 1,166,625 shares currently outstanding.
-
Authorized Share Reduction
Proposal 4 would reduce authorized common shares from 350,000,000 to 200,000,000, a governance move the Board states would make investment more attractive by limiting future dilution risk.
-
Financial Distress Context
The proxy follows a going-concern warning in the Q2 2026 10-Q, a Nasdaq delisting notice resolved in September 2026, and a cash runway that was projected to end in August 2026 — the company is seeking multiple capital-raising authorizations to fund operations.
Analysis · BIAF · Industrial Applications And Services
bioAffinity Technologies is asking shareholders to approve the exercise of warrants from its August and October 2026 private placements, which could raise up to $11.6 million in gross proceeds if exercised for cash. More significantly, the proxy seeks authorization to issue up to 10 million additional shares in future non-public offerings at discounts of up to 35% below market price — a potential dilution of roughly 857% relative to the 1.17 million shares currently outstanding. The company is simultaneously proposing to reduce authorized shares from 350 million to 200 million, a governance move that appears designed to reassure investors about dilution risk even as it seeks broad new issuance authority. This comes against a backdrop of going-concern warnings, a Nasdaq delisting notice that was recently resolved, and a cash runway that was projected to end in August 2026.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.5% of the 1494 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIAF was trading at $3.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5M. The 52-week trading range was $3.76 to $80.70. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.